Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Raw Materials (2020 - 2025)

Bioventus (BVS) has disclosed Raw Materials for 6 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials fell 3.88% year-over-year to $21.2 million, compared with a TTM value of $21.2 million through Dec 2025, down 3.88%, and an annual FY2025 reading of $21.2 million, down 3.88% over the prior year.
  • Raw Materials was $21.2 million for Q4 2025 at Bioventus, down from $21.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $26.4 million in Q3 2023 and bottomed at $3.4 million in Q4 2021.
  • Average Raw Materials over 5 years is $18.8 million, with a median of $21.6 million recorded in 2025.
  • The sharpest move saw Raw Materials skyrocketed 414.05% in 2022, then dropped 11.23% in 2024.
  • Year by year, Raw Materials stood at $12.2 million in 2021, then skyrocketed by 51.1% to $18.5 million in 2022, then rose by 14.13% to $21.1 million in 2023, then increased by 4.92% to $22.1 million in 2024, then decreased by 3.88% to $21.2 million in 2025.
  • Business Quant data shows Raw Materials for BVS at $21.2 million in Q4 2025, $21.9 million in Q3 2025, and $23.4 million in Q2 2025.